China: Precedent Fails To Help Applicants

Jiancheng Jiang of Peksung Intellectual Property describes recent case law relating to second-use inventions, and asks whether the judgments will break through China's reliance on codified laws

In China, as in other countries around the world, methods for the diagnosis and treatment of diseases may not be granted a patent right (article 25.1 of the Chinese Patent Law). Under the examination practice of the State Intellectual Property Office (SIPO), it is possible to use the so-called Swiss-type claim format for seeking protection for a second medical use invention of a substance so as to avoid the application of article 25.1. SIPO's Guidelines for Examination explicitly provides that the claim of a second medical-use invention can be drafted as "use of compound X for preparing a medicament for the treatment of disease Y". Such a claim type is considered as a use claim as it is a method for preparing a medicament (part II, chapter 10, section 4.5.2 of the Guidelines for Examination 2010), and so does not fall within the category of methods for the diagnosis and treatment of diseases. Put another way, such inventions, in terms of their subject matter, can get patent protection under the Chinese practice.

It is generally believed that the above-mentioned provision in the Guidelines for Examination is made by drawing references from the practice of the European Patent Office (EPO). Even after the EPO terminated the use of Swisstype claims through case law (EPO Enlarged Board of Appeal decision G02/08), SIPO continues to use it. Nevertheless, SIPO examination practice in this area is different from that of the EPO.

In practice, some medical use inventions contribute to prior art, mainly in discovering a new dosing regimen of a medicament (such as a new dosage amount, or dosing interval) rather than in finding out new indications. These inventions may be valuable to companies who seek innovations in the use of an existing pharmaceutical product. As to the patent applications of such inventions, the EPO explicitly admits the patentability of the second medical use claim defined by dosing regimens (EPO Enlarged Board of Appeal decision G02/08). Nevertheless, SIPO would examine whether or not the features related to using the medicament, such as the mode, route, usage amount and interval of administration, have a limiting effect on the preparation procedure of a medicament; a distinguishing feature over the prior art that is merely embodied in the course of administering the medicament does not make the claim novel (see part II, chapter 10, section 5.4 of the Guidelines for Examination). According to this examination standard, if the distinguishing features of a Swiss-type claim are merely embodied in the course of administration but cannot define the procedure of preparation of a medicament, they may not be considered in the assessment of novelty and inventiveness of the claimed invention. This examination standard prevents most inventions in China relating to a new dosing regimen from being protected.

On this issue, however, the judicial authorities of China have made judgments that are seemingly inconsistent with the examination standard.

Chinese patent ZL94194471.9

Chinese patent ZL94194471.9 relates to a second medical use invention, of which the granted claim 1 reads as:

1 The use of 17 -(N-tert-butylcarbamoyl)-4- aza-5 -androst-1-ene-3-one for the preparation of a medicament adapted for oral administration useful for the treatment of androgenic alopecia in a person and wherein said medicament comprises about 0.05-3.0 mg dosage amount of 17 -(N-tert-butylcarbamoyl)- 4-aza-5 -androst-1-ene-3-one.

In the invalidation proceedings of the patent, the Patent Reexamination Board (PRB) presented the following opinions:

This patent differs from the prior art in that: (1) the dosage amount of the medicament defined in this patent is 0.05 to 3.0 mg; and (2) this patent defines that the medicament is orally administered. Nevertheless, distinguishing feature (1) has no limiting effect on the claim, and thus shall be deemed to be nonexistent in the assessment of novelty and inventiveness; and distinguishing feature (2), as the PRB admitted, has limiting effect on the medicament product to some extent, and thus could confer novelty to claim 1.

In its invalidation decision, the PRB detailed the grounds of these findings. As to feature (1) (0.05-0.3 mg dosage amount), the PRB deemed that it has no limiting effect on the method for preparing the medicament. The PRB held that, since the use of a substance in the preparation of a medicament substantially equates to a method for preparing the medicament, only the features of raw materials, preparation steps and conditions, the form and components of the medicament product, have a direct limiting effect on the use. Administration is a step carried out after the medicament is prepared. Therefore, the preparation and administration of a medicament are two different steps, and do not coincide in terms of time domain. In order to achieve the above-mentioned dosage amount, the medicament could be administered to a patient with a smaller dosage amount more times or with a larger dosage amount fewer times. This is common knowledge in the art. The intake dosage of a medicament would have no limiting effect on the raw materials, preparation method or indications of the medicament.

As to feature (2), the PRB deemed that although the feature also concerns the method of using the medicament, it generally implies some product features of the medicament, for example, oral administration requires the auxiliaries to be suitable for oral intake, and thereby has a limiting effect on the selection of auxiliaries. Therefore, the feature does have a limiting effect on the medicament product to some extent.

Based on the above findings, the PRB considered merely feature (2) in the assessment of inventiveness of this patent, and finally made the decision that the patent has no inventiveness.

Appeal to the Higher Court

The patentee appealed to Beijing Number 1 Intermediate People's Court. The court upheld the decision of the PRB. The patentee further appealed to Beijing Higher People's Court. The Higher Court finally judged that the first instance judgment would be upheld. Noticeably, in the final judgment, an analysis different 4 to that of the PRB and the court of the first instance was made.

Specifically, the Higher Court did not agree on the findings of the PRB in terms of the limiting effect of feature (1). In particular, the Higher Court held that a medical use invention is substantively an invention of a method for administering a medicament. The technical features concerning administration of a medicament (so-called dosing characteristics, such as dosage form and amount used), should be read into the claim. In addition, the preparation of a medicament includes all the procedures before packaging for sale, and of course includes the dosing characteristics. Under the circumstances that the patentee improves the dosage form, amount, and the like, disregarding the dosing characteristics is unfavourable to the development of the pharmaceutical industry and to meeting people's need for healthcare, and does not conform to the legislative purpose of the Patent Law (Beijing Higher People's Court Administrative Judgment (2008) Gaoxingzhongzi 378).

A rare decision

This judgment of the Higher Court attracted attention from the public. In China, cases to which the court declines to apply the provisions of the Guidelines for Examination are rare. The Higher Court seemed to deem that the dosing characteristics should be treated as a part of the procedure in the preparation of a medicament (that is, having limiting effect on a medical use claim), and thus may be considered in the assessment of novelty and inventiveness. The judgment offered a glimmer of hope to companies active in this field. The judgment may have cleared the way for seeking protection for such inventions. Nevertheless, things are not so simple. As is known, Chinese practice does not necessarily follow precedent. A court judgment is binding only on the case it deals with, and not universally. In fact, after the Higher Court's judgment, SIPO did not adopt the opinions of the Higher Court, but followed the past standard when they amended the Guidelines for Examination in 2010 to match the Patent Law, as effective from October 1 2009.

Recently, a decision made by the Supreme People's Court on Patent 99812498.2 seems to put an end to the issue.

Clarification by the Supreme Court

The case was initiated before the PRB as a patent invalidation case. Claim 1 of the patent as granted reads as:

1 Use of daptomycin for the manufacture of a medicament for treating a bacterial infection in a patient in need thereof while not resulting in skeletal muscle toxicity, wherein a dose for said use is 3 to 75 mg/kg of daptomycin wherein said dose is administered repeatedly at a dose interval of once every 24 hours or 48 hours.

In the invalidation proceedings, the PRB deemed that a prior art document discloses the same medical use of daptomycin as that claimed in the present patent, with merely the dose and dose interval being different. It is well known to those skilled in the art that the features of dosage amount, repeated administration and dose interval are information to be selected and determined according to patients by doctors in the treatment process, and so constitute information involved in administration process and have nothing to do with process of manufacturing the medicament. Therefore, dosage amount, repeated administration and dose interval have no limiting effect on the medicament per se, and cannot distinguish the medical use of claim 1 from that of the prior art. In other words, the PRB deemed that these features are distinguishing features only embodied in the administration process, and so cannot bring novelty to the use of the patent. After the case was appealed to the court, the Intermediate Court as the first instance court, and the Higher Court as the second instance court, both upheld the decision of the PRB. The patentee then requested retrial before the Supreme People's Court.

The Supreme Court, in its retrial ruling, stated that Swiss-type claims involving second medical use are of process type. Such claims exclude other other manufacturers from manufacturing the same product with the same use. In this way, the technical features of such claims should still be analysed from the process claim view. Usually, it is the raw materials, preparation steps and technological conditions, the form and components of a pharmaceutical product, and the equipment used, that have limiting effect on the claims. As to the features involving merely administering a medicament (such as the dosage amount and dose interval), if they have no direct relation with the preparation of the medicament, they are actually a particular method for applying the medicament to humans after implementing the method for the preparation and obtaining the medicament. There fore, such features have no direct and necessary relation with the method for preparing the medicament; they are not technical features of the use for the preparation of a medicament, and have no limiting effect on it.

The above decision of the Supreme Court is not very surprising, as ever since the Higher Court made the judgment on patent ZL94194471.9, judicial circles have taken different views on the judgment (Tong Shu, China Patents and Trademarks No 4, 2009, pages 50- 53). Nevertheless, the ruling is important in that it is the first time the Supreme Court has made its position clear on the limiting effect of dosing regimen features on second medical use claims. In the present case, the Supreme Court explicitly endorses the examination standard implemented by SIPO on this issue.

Beyond the codified laws

It is worthwhile to note that in the invalidation proceedings of this case, the patentee submitted the judgment of the Higher Court on patent ZL 94194471.9, and requested the PRB to examine this case according to the Higher Court's opinion. As expected, the PRB declined to follow it, and the Supreme Court did not make any comments on this issue. Understandably, China is not a common law country and has no legal tradition to stare decisis, and only the codified laws can be applied by the court in trials. Nevertheless, considering the authority of the Supreme Court in the judicial system, the attitude of the Supreme Court supporting the examination standard of SIPO on this issue will very likely be followed by lower courts in the future. It is believed that, in future, if the patentee wishes to challenge this examination standard through judicial channels, there would be only a very slim chance of success.

Originally published by

Jiancheng Jiang

Jiancheng Jiang is a patent attorney and attorney-at-law whose practice area covers drafting, prosecution, re-examination, invalidation, litigation, enforcement and strategy in a wide variety of technical IP areas, particularly biochemistry, biotechnology, pharmaceutics, and organic chemistry.

Jiancheng received his BS degree in biochemistry from Peking University, Beijing, and his MS degree in biochemistry from the Graduate School of the Chinese Academy of Sciences, Beijing. He studied European patent law at the European Patent Office and US patent law in the US, and completed integrated law courses at Renmin University, Beijing. He began to practice IP law at China Patent Agent (HK) in 1987. In 2003, he founded Peksung Intellectual Property, and is now the managing partner.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.